Efficacy of Lactobacillus Mucosae DPC6426 on Blood-lipids

NCT07519967 | Completed

• 1 other identifier: AFCRO-059
• Study Type: interventional
• Target: 94
• Locations: 1 country
• Sites: 1

Brief Summary

Cardiovascular disease (CVD) is the leading cause of death and morbidity in the EU. Among the recommendations to avoid heart disease is the maintenance of normal blood cholesterol levels, by ingesting a cardioprotective diet and if necessary via the use of drugs such as statins. Low consumer compliance with dietary recommendations and the expense and side effects of drug therapy for many consumers, aligned with increased consumer acceptance of foods with additional health benefits has led to an opportunity for functional foods in the heart health area. The global market for foods with heart health benefits in the US, UK, Germany, France, Spain, Italy, Japan and Australia in 2009 was €10.84 billion (Leatherhead Food International). In apilot study in 10 mildly hypercholesterolaemic (≥5mmol/L and \<7.5mmol/L) male adults, who were administered Lb. mucosae DPC6426 daily for 6 weeks, resulted in an increase in ratio of HDL to total cholesterol from start to end of the study. Therefore, this Lactobacillus mucosae strain may lead to the development of novel functional foods and supplements with potential cardioprotective properties. Lb. mucosae DPC 6426 was benchmarked against plant sterol-esters, oat beta glucan and other probiotics strains (Lb. reuterii, NCIMB 30242) and was found to be more effective than oat beta glucan and Lb. reuterii, and similar in its effect on cholesterol as plant sterol esters. Subjects were invited to participate in this study as they gad hypercholesterolaemia (defined as cholesterol between 5.5 mmol/L and 7.9 mmol/L) The duration of your participation in this study is approximately 15-17 consecutive weeks.

Conditions

Cholesterol; Hypercholesterolaemia

Outcome Measures

Primary Outcomes (1)

• Total cholesterol

  To compare the effect of Lactobacillus mucosae DPC6426, relative to placebo, on changes in total cholesterol, from baseline to week 12, in mildly hypercholesterolaemic (\> 5.5 mmol/L and \< 8mmol/L) adults.

  Baseline to Week 12

Secondary Outcomes (5)

• Total cholesterol

  Baseline to Week 4 and Week 8

• LDL-cholesterol

  Baseline to Week 4, Week 8 and Week 12

• HDL-cholesterol

  Baseline to Week 4 Week 8 and Week 12

• Triglycerides

  Baseline to Week 4, Week 8 and Week 12

• Adverse events

  Baseline to Week 12

Study Arms (2)

Lactobacillus mucosae DPC6426

EXPERIMENTAL

Lactobacillus mucosae DPC6426

Other: Lactobacillus mucosae DPC6426

Placebo

SHAM COMPARATOR

an identical capsule without Lb. mucosae DPC6426.

Other: Placebo

Interventions

Placebo OTHER

an identical capsule without Lb. mucosae DPC6426.

Placebo

Lactobacillus mucosae DPC6426 OTHER

Lactobacillus mucosae DPC6426

Lactobacillus mucosae DPC6426

Eligibility Criteria

• Age: 20 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be able to give written informed consen
• Be between 20 and 70 years of age,
• Subjects are mildly hypercholesterolaemic, with a total cholesterol level \>5.5 mmol/L and \<8mmol/L,
• Subject has a BMI of between 18.5 - 32 Kg/m2,
• Have a stable body weight (\< 5% change) over the past 3-months, -Subject is in general good health as determined by the investigator.

You may not qualify if:

• Are less than 20 and greater than 70 years of age,
• Females are pregnant, lactating or wish to become pregnant during the study. Female subject is currently either of:
• non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or any female who is surgically sterilized (via documented hysterectomy or bilateral tubal ligation). (For purposes of this study, postmenopausal is defined as one year without menses), OR
• child bearing potential, the subject is eligible to enter and participate in this study if she is not lactating and has a negative urine pregnancy test at the screening visit, visit 2 and upon completion of the study at visit 7. The subject must also agree to one of the following methods of contraception: i. Complete abstinence from intercourse two weeks prior to administration of study drug, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the study medication in cases where subject discontinues the study prematurely. (Subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit.) or, ii. has a male sexual partner who is surgically sterilized prior to the Screen Visit and is the only male sexual partner for that subject or, iii. sexual partner(s) is/are exclusively female or, iv. Oral contraceptives (either combined or progestogen only) with double-barrier method of contraception consisting of spermicide with either condom or diaphragm. (Women of child-bearing potential using an oral contraceptive in combination with a double-barrier method of contraception are required to continue to use this form of contraception for 1 week following discontinuation of study medication), v. Use of double-barrier contraception, specifically, a spermicide plus a mechanical barrier (e.g. male condom, female diaphragm). The subject must be using this method for at least 1 week following the end of the study or, vi. Use of any intrauterine device (IUD) or contraceptive implant with published data showing that the highest expected failure rate is less than 1% per year. The subject must have the device inserted at least 2 weeks prior to the first Screen Visit, throughout the study, and 2 weeks following the end of the study.
• Subject is a smoker,
• Are hypersensitive to any of the components of the test product,
• Have a significant acute or chronic, unstable and untreated disease or any condition which contraindicates, in the investigators judgement, entry to the study,
• Subject is taking a probiotic or prebiotic product/supplement or have taken them within two weeks of the screening visit,
• Subject has received a blood transfusion within the previous 6 months,
• Subjects has taken antibiotics within the previous 3 months,
• Subject has a history of drug and/or alcohol abuse at the time of enrolment,
• Have a Gamma-GT outside the normal range,
• Have an active gastrointestinal disorder or previous gastrointestinal surgery,

Sponsors & Collaborators

• University College Cork: lead

Study Sites (1)

Unknown Facility

Cork, Co. Cork, Ireland

Location

MeSH Terms

Conditions

Hypercholesterolemia

Condition Hierarchy (Ancestors)

Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Prof. Noel Caplice

  University College Cork

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Randomised, double-blinded, placebo controlled

Study Record Dates

• First Submitted: April 2, 2026
• First Posted: April 9, 2026
• Study Start: May 30, 2016
• Primary Completion: January 18, 2017
• Study Completion: January 18, 2017
• Last Updated: April 9, 2026

Record last verified: 2026-04

Locations

IE (1)